z-logo
open-access-imgOpen Access
Characterization of a naturally occurring mutation V368M in the human glucagon receptor and its association with metabolic disorders
Author(s) -
Gonghua Lin,
Qiaofeng Liu,
Antao Dai,
Xiaoqing Cai,
Qingtong Zhou,
Xi Wang,
Yan Chen,
Chenyu Ye,
Jie Li,
Dehua Yang,
Mingwei Wang
Publication year - 2020
Publication title -
biochemical journal
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 1.706
H-Index - 265
eISSN - 1470-8728
pISSN - 0264-6021
DOI - 10.1042/bcj20200235
Subject(s) - glucagon receptor , hyperglucagonemia , glucagon , glucose homeostasis , endocrinology , medicine , biology , mutation , homeostasis , receptor , blood sugar regulation , insulin , biochemistry , insulin resistance , gene
Glucagon is a peptide hormone secreted by islet α cells. It plays crucial roles in glucose homeostasis and metabolism by activating its cognate glucagon receptor (GCGR). A naturally occurring deleterious mutation V368M in the human GCGR leads to reduced ligand binding and down-regulation of glucagon signaling. To examine the association between this mutation and metabolic disorders, a knock-in mouse model bearing homozygous V369M substitution (equivalent to human V368M) in GCGR was made using CRISPR-Cas9 technology. These GcgrV369M+/+ mice displayed lower fasting blood glucose levels with improved glucose tolerance compared with wild-type controls. They also exhibited hyperglucagonemia, pancreas enlargement and α cell hyperplasia with a lean phenotype. Additionally, V369M mutation resulted in a reduction in adiposity with normal body weight and food intake. Our findings suggest a key role of V369M/V368M mutation in GCGR-mediated glucose homeostasis and pancreatic functions, thereby pointing to a possible interplay between GCGR defect and metabolic disorders.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.
Having issues? You can contact us here